文献速递中毒与环境急症

新型精神活性物质的影响被低估:挪威奥斯陆娱乐性药物中毒的实验室确认

Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway.
PubMed 文献 · Clin Toxicol (Phila) · 2017-04-13
一句话结论奥斯陆娱乐性药物中毒患者中8%检出新型精神活性物质但临床均未怀疑,绝大多数仍为经典药物,处置应基于临床状况。

该研究在2014年4月至9月纳入奥斯陆事故与急诊门诊(OAEOC)及奥斯陆大学医院(OUH)所有娱乐性药物中毒患者共964例,分别采集口腔液(OAEOC)和血液(OUH)样本,用超高效液相色谱-串联质谱(UHPLC-MS/MS)筛查。OAEOC可分析55份口腔液,最常见为氯硝西泮42/55(76.4%)、苯丙胺类40/55(72.7%)、海洛因39/55(70.9%),7例(12.7%)检出NPS。OUH可分析103份血液,最常见为氯硝西泮51/103(49.5%)、苯丙胺类48/103(46.6%)、海洛因31/103(30.1%)、地西泮30/103(29.1%),5例(4.9%)检出NPS。所有筛查病例临床均未怀疑NPS,但总体上8%病例检出NPS,绝大多数患者仍使用经典药物。作者认为处置应基于临床状况,但需警惕不典型表现可能源于未怀疑的药物。

要点

  • 964例娱乐性药物中毒患者中,OAEOC 841例(87.2%)、OUH 123例(12.8%),可分析样本分别为55份口腔液和103份血液。
  • 所有筛查病例临床均未怀疑NPS,但OAEOC 7/55(12.7%)、OUH 5/103(4.9%)检出NPS,总体约8%。
  • OAEOC口腔液最常见为氯硝西泮42/55(76.4%)、苯丙胺类40/55(72.7%)、海洛因39/55(70.9%)。
  • OUH血液最常见为氯硝西泮51/103(49.5%)、苯丙胺类48/103(46.6%)、海洛因31/103(30.1%)、地西泮30/103(29.1%)。
  • 作者认为绝大多数患者仍使用经典药物,处置应基于临床状况,但需警惕不典型表现可能源于未怀疑的药物。

适用人群与场景

  • 2014年4月至9月在奥斯陆事故与急诊门诊(OAEOC)和奥斯陆大学医院(OUH)就诊的所有娱乐性药物中毒患者。
  • OAEOC采集口腔液样本,OUH采集血液样本。

红旗征与不能漏的情况

  • 所有筛查病例临床均未怀疑NPS,但部分病例检出NPS,作者认为需警惕不典型表现可能源于未怀疑的药物。

研究设计与关键结果

  • 研究类型为在奥斯陆两家机构进行的前瞻性注册与实验室筛查研究,共纳入964例,OAEOC 841例(87.2%)、OUH 123例(12.8%)。
  • OAEOC可分析55份口腔液,最常见为氯硝西泮42/55(76.4%)、苯丙胺类40/55(72.7%)、海洛因39/55(70.9%),7例(12.7%)检出NPS:4-甲基苯丙胺3例、二甲基色胺2例、甲酮1例、N,N-二甲基-3,4-亚甲二氧基苯丙胺1例。
  • OUH可分析103份血液,最常见为氯硝西泮51/103(49.5%)、苯丙胺类48/103(46.6%)、海洛因31/103(30.1%)、地西泮30/103(29.1%),5例(4.9%)检出NPS:JWH-210 2例、AM-2201 2例、5-EAPB 1例。
  • 所有筛查病例临床均未怀疑NPS,但总体上8%病例检出NPS,绝大多数患者仍使用经典药物。

证据类型、等级与局限

  • 证据类型为前瞻性注册与实验室筛查研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为娱乐性药物中毒患者的处置应基于其临床状况。
  • 作者认为需高度警惕不典型表现可能源于未怀疑的药物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: Recreational drug toxicity is frequent. Availability of new psychoactive substances is steadily increasing. However, data with verified analyses from clinical settings are limited. To evaluate the impact of novel psychoactive substances (NPS) on recreational drug toxicity in Oslo, Norway, we analysed samples from a selection of patients.

METHODS: All the patients presenting with recreational drug toxicity at the Oslo Accident and Emergency Outpatient Clinic (OAEOC) and at the Oslo University Hospital (OUH) were registered from April through September 2014. Oral fluid samples were collected at the OAEOC. Blood samples were collected at the OUH. The samples were screened using ultra-high performance liquid chromatography - tandem mass spectrometry (UHPLC-MS/MS).

RESULTS: Nine hundred and sixty-four cases were included, 841 (87.2%) at the OAEOC and 123 (12.8%) at the OUH. A total of 55 oral fluid samples (OAEOC) and 103 blood samples (OUH) could be analysed. NPS were not clinically suspected in any of the screened cases. At the outpatient clinic, the most commonly found substances were clonazepam in 42/55 (76.4%) cases, amfetamines in 40/55 (72.7%) and heroin in 39/55 (70.9%). In seven (12.7%) cases NPS were detected: 4-methylamfetamine in three cases, dimethyltryptamine in two, methylone in one, and N,N-dimethyl-3,4-methylenedioxyamfetamine in one. Among the hospital patients, the most commonly found substances were clonazepam in 51/103 (49.5%) cases, amfetamines in 48/103 (46.6%), heroin in 31/103 (30.1%), and diazepam in 30/103 (29.1%). In five (4.9%) cases NPS were detected: JWH-210 in two cases, AM-2201 in two, and 5-EAPB in one.

CONCLUSION: NPS were clinically not suspected, though found in eight percent of cases. Still, the vast majority of patients treated for recreational drug toxicity in Oslo have taken classical drugs. Management of these patients should be based on their clinical condition. However, it is highly important to be alert to atypical presentations possibly resulting from unsuspected drugs.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Vallersnes OM, Persett PS, Øiestad EL, et al. Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway. Clin Toxicol (Phila). 2017. PMID: 28406320. doi:10.1080/15563650.2017.1312002

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。